"The U.S. Food and Drug Administration today approved Orbactiv (oritavancin), a new antibacterial drug to treat adults with skin infections.
Orbactiv is approved to treat patients with acute bacterial skin and skin structure infections (ABSS"...
In controlled clinical trials, 9 (approximately 1%) of 815 patients treated with Mentax® (butenafine) Cream, 1%, reported adverse events related to the skin. These included burning/stinging, itching, and worsening of the condition. No patient treated with Mentax® (butenafine) Cream, 1%, discontinued treatment due to an adverse event. In the vehicle-treated patients, two of 718 patients discontinued because of treatment-site adverse events, one of which was severe burning/stinging and itching at the site of application.
In uncontrolled clinical trials, the most frequently reported adverse events in patients treated with Mentax® (butenafine) Cream, 1%, were: contact dermatitis, erythema, irritation, and itching, each occurring in less than 2% of patients.
In provocative testing in over 200 subjects, there was no evidence of allergic contact sensitization for either the cream or the vehicle base for Mentax® (butenafine) Cream, 1%.
Read the Mentax (butenafine) Side Effects Center for a complete guide to possible side effects
Potential drug interactions between Mentax® (butenafine HCl cream) Cream, 1%, and other drugs have not been systematically evaluated.
Last reviewed on RxList: 4/3/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Mentax Information
Mentax - User Reviews
Mentax User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.